SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

ETICOVO

TEVA·Teva Pharmaceutical Industries Ltd
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Eticovo is already FDA-approved (since 2019) but is blocked from U.S. commercial launch by Amgen's patent injunction until at least 2029. Teva obtains U.S. commercialization rights upon deal close (expected by end of 2026), but cannot generate revenue until the patent barrier lifts.
Why 4/10
Eticovo is already FDA-approved (since 2019) with no pending PDUFA or pivotal readout; the next hard catalyst would be its U.S. market launch, which is blocked by Amgen's patent injunction until at least 2029, more than 12 months away. As an approved drug with no imminent binary catalyst at a large diversified pharma company, the impact score is low.
Actionable Insight NEUTRAL

The key event is today's (Nov 3, 2026) deal with Samsung Bioepis giving Teva U.S. commercialization rights to Eticovo upon close. However, Eticovo remains blocked from the U.S. market by Amgen's Enbrel patents until at least 2029, so near-term revenue is zero. Watch for the deal closing (expected by end of 2026) and any patent-litigation developments that could shift the 2029 launch timeline.

Price Chart

Loading chart...

Executive Summary

Eticovo (etanercept-ykro) is an FDA-approved biosimilar to Amgen's blockbuster anti-inflammatory drug Enbrel, developed by Samsung Bioepis. On November 3, 2026, Teva announced a deal worth up to $420 million to commercialize Eticovo and another biosimilar (Renflexis) in the U.S. However, Eticovo has been blocked from the U.S. market since its 2019 approval by Amgen's patent litigation, with a permanent injunction preventing launch until at least 2029. For Teva, a large diversified pharma company, this deal adds a long-dated pipeline asset with no near-term revenue contribution.

How It Works

Eticovo is a biosimilar (a near-identical copy) of Enbrel (etanercept), a biologic drug that blocks tumor necrosis factor (TNF), a protein that drives inflammation in autoimmune diseases. By neutralizing TNF, Eticovo reduces inflammation and symptoms in conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.

Trial Status

Eticovo received FDA approval in 2019 based on a Phase III study demonstrating comparable efficacy and safety to the reference product Enbrel (etanercept). It is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis but has not been commercially launched in the U.S. due to patent litigation.

The Two-Sided Case

▲ Bull Case4
Teva secured U.S. commercialization rights to an already FDA-approved biosimilar (approved 2019) with a established safety and efficacy profile, avoiding development risk.
The deal expands Teva's biosimilar portfolio under its Pivot to Growth strategy, adding a product that targets a large autoimmune market (Enbrel had multi-billion-dollar annual sales before biosimilar erosion).
Analyst consensus on TEVA is strong buy (6 buy/strong-buy vs 1 hold, 0 sell) with a mean price target of $47.92, implying ~17.7% upside from the $40.70 close, per the latest snapshot.
Institutional accumulation was heavy in Q2 2026, with Capital World Investors adding 41.9% ($424.7M position), William Blair doubling (362.5% increase), and UBS AM increasing 6,595%.
▼ Bear Case4
Eticovo is blocked from the U.S. market by a permanent injunction from Amgen's Enbrel patent litigation, preventing any sales until at least 2029, per multiple sources including Fierce Pharma and Drug Patent Watch.
Teva is a large, diversified pharma company (market cap implied ~$40B+ at ~$40/share), so Eticovo's potential contribution is small relative to the whole enterprise.
The deal's $420 million total value is split across two products (Eticovo and Renflexis) and is mostly milestone- and royalty-based, not guaranteed upfront cash.
Teva faces significant insider selling (director Roberto Mignone sold $14.4M worth of shares in September 2026) and mixed institutional signals, with several tracked managers exiting or trimming TEVA positions in Q3 2026.

Upcoming Catalysts

  • Closing of the Samsung Bioepis commercialization deal (expected by end of 2026)
  • U.S. market entry for infliximab-abda (Renflexis biosimilar) in Q3 2027 (the second product in the deal)
  • Any patent-litigation developments that could shift the 2029 U.S. launch timeline for Eticovo

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Teva Pharmaceutical Industries Ltd Press Release TEVA ·Originating report

Sources · 13

Hover a chip for the title
1 drugs.com2 drugs.com3 accessdata.fda.gov4 accessdata.fda.gov5 en.sedaily.com6 biz.chosun.com7 globenewswire.com8 stocktitan.net9 finance.biggo.com10 fiercepharma.com11 centerforbiosimilars.com12 pharmadossier.com13 sec.gov